A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02102256
Recruitment Status : Recruiting
First Posted : April 2, 2014
Last Update Posted : May 10, 2018
Keck School of Medicine of USC
Children's Hospital Los Angeles
Huntington Medical Research Institutes
Information provided by (Responsible Party):
Laurie Eisenberg, University of Southern California

Brief Summary:
Current treatment options for bilateral profoundly deaf children, diagnosed with inner ear anatomical abnormalities, are limited and, in the case of absent cochleas, non-existent. An auditory brainstem implant (ABI) places an electrode close to the auditory nucleus in the brainstem. Children aged 2 - 5 who are not candidates for a cochlear implant, or who did not demonstrate benefit from a cochlear implant, will be implanted with an ABI and followed for 1 year for safety and a total of 3 years for preliminary efficacy. This is a feasibility study to determine the safety of the ABI.

Condition or disease Intervention/treatment Phase
Profound Bilateral Deafness Due to Bilateral Cochlear Aplasia Bilateral Cochlear Nerve Deficiency Bilateral Cochlear Ossification Secondary to Meningitis Device: Auditory Brainstem Implant Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Study Start Date : March 2014
Estimated Primary Completion Date : November 2019

Arm Intervention/treatment
Experimental: Experimental
Device Implantation
Device: Auditory Brainstem Implant
Other Name: Cochlear Corporation Nucleus 24

Primary Outcome Measures :
  1. Primary endpoint [ Time Frame: 12-months post-device activation ]
    Serious adverse event (count) per subject. Count of expected serious adverse events per subject.

Secondary Outcome Measures :
  1. Secondary endpoint: Preliminary efficacy [ Time Frame: 3 years post-device activation ]
    Access to sound at a level (dB) and with the frequency range (500-4000Hz), known to be associated with speech.

  2. Unexpected Serious Adverse Events [ Time Frame: 12-months post-activation ]
    Unexpected adverse events (count).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Bilateral profound deafness due to cochlear aplasia, cochlear nerve deficiency, or ossification secondary to meningitis
  • If previously received a cochlear implant, must demonstrate lack of benefit from that device

Exclusion Criteria:

  • Medical contraindication to craniotomy/intracranial surgery
  • Severe cognitive or developmental delays

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02102256

Contact: Amy Martinez, MS 213-764-2807
Contact: Laurie Eisenberg, PhD 213-764-2826

United States, California
Keck School of Medicine of USC Recruiting
Los Angeles, California, United States, 90008
Contact: Amy Martinez, MS    213-764-2807   
Principal Investigator: Laurie Eisenberg, PhD         
Children's Hospital Los Angeles Active, not recruiting
Los Angeles, California, United States
Sponsors and Collaborators
Laurie Eisenberg
Keck School of Medicine of USC
Children's Hospital Los Angeles
Huntington Medical Research Institutes
Principal Investigator: Laurie S. Eisenberg, PhD Keck School of Medicine of USC
Principal Investigator: Eric Wilkinson, MD Huntington Medical Research Institute

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Laurie Eisenberg, Professor of Research Otolaryngology, University of Southern California Identifier: NCT02102256     History of Changes
Other Study ID Numbers: KSOM-ABI 001
First Posted: April 2, 2014    Key Record Dates
Last Update Posted: May 10, 2018
Last Verified: May 2018

Keywords provided by Laurie Eisenberg, University of Southern California:

Additional relevant MeSH terms:
Hearing Loss
Central Nervous System Diseases
Nervous System Diseases
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Signs and Symptoms